Spinal Dural Arteriovenous Fistula(SDAVF)
Conditions
Interventions
Control group (conventional treatment group):Control group: Conventional treatment intervention
Intervention group (astaxanthin + leucine + niacinamide combination group):Astaxanthin + Leucine + Nicotinic Acid Derivatives Combined Use
Sponsors
Drum Tower Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1.Case Group Age: 18-75 Years; 2.Diagnosed as spinal vascular disease by spinal DSA/MRI; 3.ASIA Score Grade C and above; 4.Sign the informed consent form;
Exclusion criteria
Exclusion criteria: 1.Complicated with other nervous system diseases (e.g., multiple sclerosis, spinal cord tumors); 2.Severe systemic diseases (e.g., end-stage liver and kidney failure, malignant tumors); 3.Pregnant or lactating women;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Proportion of patients with ASIA score improvement >=1 grade after 6 months;Combined biomarkers: sensitivity and specificity; | — |
Secondary
| Measure | Time frame |
|---|---|
| Incidence of common adverse events (gastrointestinal discomfort, rash, abnormal liver function, etc.);Judgment error of therapeutic time window;Decrease amplitude of the blood-brain barrier permeability index level;Incidence of severe adverse events (allergic reactions, irreversible neurological deterioration, etc.);Fusion accuracy of multi-omics dynamic embedding fusion algorithm (MIDE);AUC value of NeuroDynaPredict 2.0; | — |
Countries
China
Contacts
Public ContactDai wei
Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School
Outcome results
None listed